This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Robinson, J. A. Articles by Spelsberg, T. C. Search for Related Content PubMed PubMed Citation Articles by Robinson, J. A. Articles by Spelsberg, T. C.

Estrogen Regulation of Human Osteoblastic Cell Proliferation and Differentiation¹

Departments of Biochemistry and Molecular Biology (J.A.R., T.C.S.) and Orthopedic Research (S.A.H.), and Division of Endocrinology (B.L.R.), Mayo Foundation, Rochester, Minnesota 55905

Address all correspondence and requests for reprints to: John A. Robinson, Ph.D., Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905. E-mail: robinson.john{at}mayo.edu

Estrogen (E₂) has been shown to prevent bone loss among postmenopausal women. The molecular mechanism(s) by which this is accomplished is not clear. The discovery of E₂ receptor (ER) in osteoblasts and osteoclasts has implicated these cells as direct targets for E₂. Previous studies on the effects of E₂ on osteoblastic cells in vitro or in organ culture present conflicting results, possibly due to heterogeneity in cell types, stage of differentiation, ER levels, and/or species differences. The effects of E₂ on gene expression during various stages of human osteoblast cell differentiation has not been investigated extensively. In this study we employed a newly developed human fetal osteoblastic cell line (hFOB/ER9) that contains high levels of ER to examine the effects of E₂ on osteoblast proliferation and differentiation. The basal levels and E₂ effects on the expression of various extracellular matrix proteins were also characterized throughout different stages of differentiation. These stages include a proliferative/relatively undifferentiated stage (day 6), a matrix maturation stage (days 10–14), and a mineralization/calcified nodule stage (day 18). During the stage of rapid cell proliferation, E₂ treatment of hFOB/ER9 cells resulted in a dose-dependent decrease in [³H]thymidine incorporation to a maximum of 72% compared to the vehicle control value. Treatment of hFOB/ER9 cells with 10^-9 M E₂ for 48 h resulted in an increase in alkaline phosphatase (AP) activity throughout cell differentiation. The magnitude of AP induction varied from 200–500%. In contrast, E₂ decreased osteocalcin protein levels to a minimum of 54% compared to the vehicle control value. The steady state messenger RNA levels for AP increased and osteocalcin decreased after E₂ treatment, similar to the responses observed at the protein level. At all stages, there was little or no effect of E₂ on type I collagen protein levels or osteonectin steady state messenger RNA levels. The E₂ responses on hFOB/ER9 cell matrix protein expression and cell proliferation were mediated through the ER, as cultures cotreated with a 100-fold molar excess of a type II anti-E₂ (ICI 182,780) abrogated these effects. These results support the hypothesis that E₂ does have an effect on osteoblastic differentiation by decreasing hFOB/ER9 cell proliferation and differentially regulating extracellular matrix expression.

This article has been cited by other articles:

				K. Janssens, P. ten Dijke, S. Janssens, and W. Van Hul Transforming Growth Factor-{beta}1 to the Bone Endocr. Rev., October 1, 2005; 26(6): 743 - 774. [Abstract] [Full Text] [PDF]

				C. Meier, P. Y. Liu, L. P. Ly, J. de Winter-Modzelewski, M. Jimenez, D. J. Handelsman, and M. J. Seibel Recombinant Human Chorionic Gonadotropin But Not Dihydrotestosterone Alone Stimulates Osteoblastic Collagen Synthesis in Older Men with Partial Age-Related Androgen Deficiency J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 3033 - 3041. [Abstract] [Full Text] [PDF]

				R. Okazaki, D. Inoue, M. Shibata, M. Saika, S. Kido, H. Ooka, H. Tomiyama, Y. Sakamoto, and T. Matsumoto Estrogen Promotes Early Osteoblast Differentiation and Inhibits Adipocyte Differentiation in Mouse Bone Marrow Stromal Cell Lines that Express Estrogen Receptor (ER) {alpha} or {beta} Endocrinology, June 1, 2002; 143(6): 2349 - 2356. [Abstract] [Full Text] [PDF]

				M. N. Dieudonne, R. Pecquery, M. C. Leneveu, and Y. Giudicelli Opposite Effects of Androgens and Estrogens on Adipogenesis in Rat Preadipocytes: Evidence for Sex and Site-Related Specificities and Possible Involvement of Insulin-Like Growth Factor 1 Receptor and Peroxisome Proliferator-Activated Receptor {gamma}2 Endocrinology, February 1, 2000; 141(2): 649 - 656. [Abstract] [Full Text] [PDF]

				T. C. Spelsberg, M. Subramaniam, B. L. Riggs, and S. Khosla The Actions and Interactions of Sex Steroids and Growth Factors/Cytokines on the Skeleton Mol. Endocrinol., June 1, 1999; 13(6): 819 - 828. [Full Text]

				P. V. N. Bodine, R. A. Henderson, J. Green, M. Aronow, T. Owen, G. S. Stein, J. B. Lian, and B. S. Komm Estrogen Receptor-{alpha} Is Developmentally Regulated during Osteoblast Differentiation and Contributes to Selective Responsiveness of Gene Expression Endocrinology, April 1, 1998; 139(4): 2048 - 2057. [Abstract] [Full Text] [PDF]

				K. R. Tau, T. E. Hefferan, K. M. Waters, J. A. Robinson, M. Subramaniam, B. L. Riggs, and T. C. Spelsberg Estrogen Regulation of a Transforming Growth Factor-{beta} Inducible Early Gene That Inhibits Deoxyribonucleic Acid Synthesis in Human Osteoblasts Endocrinology, March 1, 1998; 139(3): 1346 - 1353. [Abstract] [Full Text] [PDF]

				T. E. Hefferan, G. G. Reinholz, D. J. Rickard, S. A. Johnsen, K. M. Waters, M. Subramaniam, and T. C. Spelsberg Overexpression of a Nuclear Protein, TIEG, Mimics Transforming Growth Factor-beta Action in Human Osteoblast Cells J. Biol. Chem., June 30, 2000; 275(27): 20255 - 20259. [Abstract] [Full Text] [PDF]